SCHEMBL6770280

SCHEMBL6770280

NC(=O)c1cccc2c1c1c(O)cc(-c3ccccc3)cc1n2Cc1cccc(Oc2ccccc2)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 3/20 0.40
PLA2G1B P04054 1/20 0.40
FAAH O00519 3/20 0.39
SIRT2 Q8IXJ6 1/20 0.39
SIRT1 Q96EB6 1/20 0.39
ICMT O60725 3/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SYK P43405 1/20 0.38
MGLL Q99685 1/20 0.38
PLA2G10 O15496 1/20 0.37
CCR8 P51685 2/20 0.37
PTGES O14684 1/20 0.37
ALOX5 P09917 1/20 0.37
CTNNB1 P35222 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6774857 0.93 FAAH (0.43) PLA2G2AFAAHICMTLMNACCR8
SCHEMBL6696960 0.91 PLA2G2A (0.47) PLA2G2AFAAHSIRT2SIRT1KDM4E
SCHEMBL6770631 0.90 PLA2G2A (0.46) PLA2G2APLA2G1BFAAHSIRT2SIRT1
SCHEMBL6694433 0.90 PLA2G2A (0.46) PLA2G2APLA2G1BKDM4EALDH1A1SMN1; SMN2
SCHEMBL6775435 0.89 PLA2G2A (0.40) PLA2G2AFAAHSIRT2SIRT1KDM4E
SCHEMBL6776978 0.89 PLA2G2A (0.42) PLA2G2APLA2G1BFAAHSIRT2SIRT1
SCHEMBL6894773 0.88 FAAH (0.43) PLA2G2APLA2G1BFAAHKDM4EALDH1A1
SCHEMBL7965122 0.87 PLA2G2A (0.51) PLA2G2APLA2G1BPLA2G10
SCHEMBL6774933 0.87 PLA2G2A (0.42) PLA2G2APLA2G1BPLA2G10
SCHEMBL6771968 0.87 PLA2G2A (0.38) PLA2G2AFAAHSIRT2SIRT1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed